Novocure Announces Tumor Treating Fields Therapy Coverage for Newly Diagnosed Glioblastoma Patients in Spain.

Novocure announces that Tumor Treating Fields (TTFields) therapy is now covered by Spain's Ministry of Health for newly diagnosed glioblastoma patients through the Spanish National Health System. The therapy disrupts cancer cell division and is available in multiple countries, with reimbursement in Austria, France, Germany, Israel, Japan, Sweden, Switzerland, and the US. Over 35,000 patients have been treated globally.

Novocure (NASDAQ: NVCR) has announced that Tumor Treating Fields (TTFields) therapy is now available through the Spanish National Health System (SNS) for newly diagnosed glioblastoma patients. This development marks an expansion of coverage for the innovative cancer treatment, which disrupts cancer cell division using electric fields administered through a wearable medical device.

TTFields therapy has received a CE Mark for the treatment of newly diagnosed and recurrent WHO Grade 4 Glioma in adults and is commercially available in multiple countries across North America, Europe, and Asia. It is currently reimbursed in Austria, France, Germany, Israel, Japan, Sweden, Switzerland, and the United States. Globally, over 35,000 patients have been treated with TTFields therapy [1].

The Spanish Ministry of Health has made TTFields therapy available for patients with newly diagnosed glioblastoma who meet specific eligibility criteria. The therapy can be accessed through hospitals and health centers qualified to offer the treatment. This move aims to provide more patients with access to a potentially life-extending treatment option.

About Novocure
Novocure is a global oncology company focused on extending survival for patients with aggressive forms of cancer. The company's innovative therapy, Tumor Treating Fields, is approved in certain countries for the treatment of adult patients with glioblastoma, non-small cell lung cancer, malignant pleural mesothelioma, and pleural mesothelioma. Novocure has several ongoing or completed clinical trials exploring the use of TTFields therapy in various types of cancer [2].

Forward-Looking Statements
This press release includes forward-looking statements that reflect Novocure's current expectations or forecasts of future events. These statements may include anticipated scientific progress, clinical trial results, development of potential products, and market prospects for its products. Investors are cautioned that actual results may differ materially from those reflected in these forward-looking statements [3].

References:
[1] https://www.stocktitan.net/news/NVCR/novocure-announces-coverage-of-tumor-treating-fields-tt-fields-iqx4kdviiae0.html
[2] https://www.novocure.com
[3] https://www.novocure.com/investors